Chronic idiopathic urticaria (CIU) is a troublesome disorder with anunknown etiological agent. Mast cell activation and release of mediators occurin all forms of urticaria. Although histamine is the principal inflammatorymediator of mast cell derivation, other mediators are freed after mast cellactivation such as cysteinyl leukotrienes (leukotrienes C4, D4, and E4).1 We evaluatethe efficacy and tolerability of an antileukotriene drug, montelukast sodium,2 in relation to fexofenadine hydrochloride, an antihistaminicdrug, in patients affected by CIU.
This model of variance analysis shows that the reduction of symptomsis highly significant at later times of observation (Friedman test, 72.56; P<.001). The total symptom scores of the patients treated with fexofenadinewere on the average worse than those obtained from the montelukast-treatedpatients (Kruskal-Wallis, 8.18; P<.005), although the reductionin the time of the symptomatic profile is essentially the same for both drugs(the interaction between treatment and time of observation is not significant).t0 Indicates the time of measurement as before treatment began;t1, 10 days after treatment began; t2, 20 days aftertreatment began; and t3, 30 days after treatment began.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 29
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.